LONDON — Global pressure on health spending is forcing the $1-trillion-a-year pharmaceutical industry to look for new ways to price products: charging based on how much they improve patients’ health, rather than how many pills or vials are sold.In the US, both parties are promising fresh action on drug prices, whoever wins the White House. In Europe, economies are stalled, squeezing state health budgets. In China and other Asian markets, governments are getting tougher with suppliers.Pricing drugs based on clinical outcomes is one way to ensure that limited funds bring the most benefits to patients now and pay for the most promising medical advances in future.Some experiments in pricing have already been made.But shifting the overall industry to a new model requires improvements in data collection and a change in thinking, say drug pricing experts."Eventually, we are going to get there," said Kurt Kessler, managing principal at ZS Associates in Zurich, which advises companies on sal...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.